Clinical Trial: Fruit and Vegetable Extracts in Treating Patients With Stage I, Stage II, Stage III, Stage IVA, or Stage IVB Head and Neck Cancer

This study is currently recruiting patients.

Sponsors and Collaborators: Comprehensive Cancer Center of Wake Forest University
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)


RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Fruit and vegetable extracts may be effective in preventing the recurrence or further development of head and neck cancer.

PURPOSE: This randomized phase II trial is studying how well fruit and vegetable extracts work in preventing the recurrence of stage I, stage II, stage III, stage IVA, or stage IVB head and neck cancer.

Condition Treatment or Intervention Phase
Hypopharyngeal Cancer
Laryngeal Cancer
lip and oral cavity cancer
Oropharyngeal Cancer
 Drug: fruit and vegetable extracts
 Procedure: biologically based therapies
 Procedure: cancer prevention intervention
 Procedure: chemoprevention of cancer
 Procedure: complementary and alternative therapy
 Procedure: herbal medicine / botanical therapy
 Procedure: nutritional supplementation
Phase II

MedlinePlus related topics:  Head and Neck Cancer;   Oral Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Randomized Study of Fruit and Vegetable Extracts in Patients With Stage I-IVB Head and Neck Cancer

Further Study Details: 


  • Compare the disease-free survival of patients with stage I-IVB head and neck cancer treated with fruit and vegetable extracts vs placebo.
  • Compare the effect of these extracts on biomarkers (p27 expression, cell proliferation of Ki-67, DNA damage, and T-cell function) in these patients.
  • Correlate changes in biomarkers with other factors (e.g., site and stage of the original tumors, tobacco/alcohol use, or depression) in patients treated with these extracts.
  • Compare serum carotenoids and antioxidant levels (vitamins A, C, and E) at baseline and posttreatment in patients treated with these extracts.

OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are stratified according to tobacco use (yes vs no), alcohol consumption (yes vs no), and tumor stage at diagnosis (I vs II vs III vs IVA vs IVB). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral fruit and vegetable extracts twice daily.
  • Arm II: Patients receive oral placebo twice daily. Treatment in both arms continues for 12 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed annually for 5 years.

PROJECTED ACCRUAL: A total of 200 patients (100 per treatment arm) will be accrued for this study within 18 months.


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both



  • Curatively treated stage I-IVB squamous cell carcinoma of the upper aerodigestive tract of 1 of the following primary sites:
  • Oral cavity
  • Oropharynx
  • Hypopharynx
  • Larynx
  • Disease-free for at least 6 months and no more than 3 years after completion of surgery, radiotherapy, and/or chemotherapy
  • No synchronous tumors


  • 18 and over

Performance status

  • Karnofsky 70-100% OR
  • Zubrod 0-1

Life expectancy

  • At least 6 months


  • Hemoglobin > 10 g/dL
  • WBC ≥ 3,000/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Bilirubin ≤ 1.5 mg/dL
  • SGOT ≤ 40 U/L
  • SGPT ≤ 56 U/L


  • Creatinine ≤ 1.5 mg/dL


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except curatively treated head and neck squamous cell carcinoma, nonmelanoma skin cancer, or carcinoma in situ of the cervix
  • No other serious medical or psychiatric illness that would preclude giving informed consent
  • No nausea ≥ grade 2


  • Not specified


  • See Disease Characteristics
  • More than 6 months and less than 3 years since prior chemotherapy
  • No concurrent chemotherapy
  • No other concurrent chemopreventive agents

Endocrine therapy

  • More than 6 months and less than 3 years since prior hormonal therapy


  • See Disease Characteristics
  • More than 6 months and less than 3 years since prior radiotherapy
  • No concurrent radiotherapy


  • See Disease Characteristics
  • More than 6 months since prior surgery
  • No concurrent surgery


  • More than 6 months and less than 3 years since prior investigational agents
  • More than 2 months since prior high-dose vitamins (i.e., 10 times the recommended daily allowance [8,000-10,000 IU of vitamin A, 600 mg of vitamin C, or 80-100 IU of vitamin E])

Location and Contact Information

      MBCCOP - LSU Health Sciences Center, New Orleans,  Louisiana,  70112,  United States; Recruiting
Jill Gilbert, MD  504-568-5613 

North Carolina
      Comprehensive Cancer Center at Wake Forest University, Winston Salem,  North Carolina,  27157-1030,  United States; Recruiting
Edward G. Shaw, MD  336-716-4647 

Study chairs or principal investigators

Steven Alan Akman, MD,  Study Chair,  Comprehensive Cancer Center of Wake Forest University   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000310184; CCCWFU-0112; CCCWFU-60A02; CCCWFU-BG03-161; NCT00064298
Record last reviewed:  January 2005
Last Updated:  February 7, 2005
Record first received:  July 8, 2003 Identifier:  NCT00064298
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005